The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
Open accessAbstract
Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from different endocrine glands (such as the pituitary, the parathyroid or the neuroendocrine adrenal glands), endocrine islets (within the thyroid or pancreas) as well as from endocrine cells dispersed between exocrine cells throughout the digestive and respiratory tracts. The development of somatostatin analogues (SSA) as important diagnostic and treatment tools has revolutionised the clinical management of patients with NETs. However, although symptomatic relief and stabilisation of tumour growth for various periods of time are observed in many patients treated with SSA, tumour regression is rare. Possible mechanisms when this does occur include antagonism of local growth factor release and effects, probably including activation of tyrosine and serine-threonine phosphatases, and indirect effects via anti-angiogenesis. The development of new SSA, new drug combination therapies and chimaeric molecules should further improve the clinical management of these patients, as should a more complete understanding of their mode of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immune-neuro-endocrine interactions: facts and hypotheses.
BESEDOVSKY, H. O., & REY, A. D. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-1-64 · Cited by 1,564
mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
Functioning insulinoma—incidence, recurrence, and long-term survival of patients: a 60-year study.
SERVICE, F. J., McMAHON, M. M., O'BRIEN, P. C., & BALLARD, D. J. (1991) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)62083-7 · Cited by 883
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Cited by
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Self-citationNothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
Cancer Treatment Using Peptides: Current Therapies and Future Prospects
Thundimadathil, J. (2012) · Journal of Amino Acids · doi:10.1155/2012/967347 · Cited by 491
Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease
Torres, V. E., & Harris, P. C. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040398 · Cited by 289
Somatostatin Analogs in Clinical Practice: A Review
Gomes-Porras, M., Cárdenas-Salas, J., & Álvarez-Escolá, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051682 · Cited by 264
Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives
Modica, R., Liccardi, A., Minotta, R., Cannavale, G., Benevento, E., & Colao, A. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099840 · Cited by 37
Metadata
- Authors
- Grozinsky-Glasberg, S., Shimon, I., Korbonits, M., & Grossman, A. B.
- Venue
- Endocrine Related Cancer
- Publisher
- Bioscientifica
- Published
- 2008-05-22
- Volume
- 15
- Issue
- 3
- Pages
- 701-720
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2125450370
- Cited by
- 183
- References
- 4
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.